Aravive
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-12-10
- Employees
- 23
- Market Cap
- -
- Website
- http://www.aravive.com
- Introduction
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04983407
- Locations
- 🇺🇸
UCLA Health, Santa Monica, California, United States
🇺🇸Boca Raton Regional Hospital / Lynn Cancer Institute, Boca Raton, Florida, United States
🇺🇸Moffit Cancer Center, Tampa, Florida, United States
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT04729608
- Locations
- 🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Disney Family Cancer Center, Burbank, California, United States
🇺🇸Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04300140
- Locations
- 🇺🇸
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04042623
- Locations
- 🇺🇸
Moonshine Clinical Research, Doral, Florida, United States
🇺🇦Institute of Nephrology National Academy of Medical Science Ukraine, Kyiv, Ukraine
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Aravive, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03639246
- Locations
- 🇺🇸
Arizona Oncology, Phoenix, Arizona, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Kaiser Permanente Oakland, Oakland, California, United States
- Prev
- 1
- 2
- Next